PCOS Monitoring Schedule: Exact Lab Tests, Timelines, and Follow-Up Intervals

Baseline Diagnostic Workup: What Gets Ordered First

The initial evaluation establishes which PCOS phenotype a patient has and identifies metabolic risks that shape everything that follows. International PCOS guidelines recommend confirming the diagnosis with the Rotterdam criteria before setting a monitoring plan.

At the first visit, clinicians typically order total testosterone, free testosterone (calculated or measured by equilibrium dialysis), sex hormone-binding globulin (SHBG), DHEA-S, and 17-hydroxyprogesterone to rule out non-classic congenital adrenal hyperplasia, along with TSH and prolactin to exclude thyroid dysfunction and hyperprolactinemia, both of which can mimic PCOS. Clinical guidance identifies free testosterone as generally the most sensitive single marker of biochemical hyperandrogenism, and notes it can pick up androgen excess in some patients whose total testosterone falls within the normal range.

Pelvic ultrasound is not required for diagnosis in adults if both oligo/anovulation and hyperandrogenism are already present. When only one criterion is met clinically, transvaginal ultrasound helps confirm or exclude the ovarian morphology criterion. Work revisiting the diagnostic thresholds for follicle count and AMH found that a count of 20 or more follicles per ovary, using modern transducers, better distinguishes polycystic from normal ovarian morphology than older thresholds [3]. For adolescents within 8 years of menarche, the 2023 guideline advises against using ultrasound for diagnosis at all, since polycystic-appearing ovaries are a normal finding during that developmental window.

Metabolic Screening: OGTT, Insulin, and HbA1c Timing

PCOS is associated with a substantially higher risk of type 2 diabetes than the general population, which is why the American Diabetes Association's 2024 Standards of Care recommend screening all women with PCOS for prediabetes and diabetes at diagnosis [4]. Reported risk multipliers vary across study populations, so treat any single number with caution; the screening recommendation itself is the well-supported part.

A 75-g oral glucose tolerance test (OGTT) is the preferred screening method. HbA1c alone can miss a meaningful share of glucose abnormalities in PCOS populations, a gap documented in a PCOS-specific meta-analysis [5]. Fasting insulin can be measured alongside the OGTT, though the 2023 international guideline notes that no validated cutoff for "insulin resistance" exists and recommends against using fasting insulin alone as a diagnostic criterion.

Repeat timing depends on the baseline finding:

• Normal OGTT at baseline: repeat every 1 to 3 years, with the shorter interval (annually) for a BMI of 25 kg/m² or higher, a family history of type 2 diabetes, or advancing age.
• Impaired glucose tolerance at baseline: repeat annually, and consider metformin per current endocrinology consensus guidance [6].
• On metformin or a GLP-1 receptor agonist: check HbA1c or OGTT every 6 to 12 months to assess response and guide dosing.

HbA1c is a reasonable tool for longitudinal tracking once a baseline OGTT has been done, but it should not replace the initial OGTT.

Lipid and Cardiovascular Risk Monitoring

Dyslipidemia is common in PCOS, with a systematic review reporting elevated rates that ran as high as roughly 70% in the populations studied, though estimates vary by cohort and which lipid parameter is measured [7]. The typical pattern is elevated triglycerides, reduced HDL cholesterol, and more small, dense LDL particles.

A fasting lipid panel should be drawn at diagnosis and repeated every 1 to 2 years regardless of the baseline result, per AACE 2022 guidance [6]. Blood pressure should be checked at every visit. Women with PCOS have higher rates of hypertension than age-matched peers in the literature, and elevation can appear before a formal metabolic syndrome diagnosis, which is the practical reason to check it routinely rather than only when other risk factors appear.

For women over 40, or younger women with multiple risk factors (obesity, prediabetes, dyslipidemia, smoking, family history of premature cardiovascular disease), the 2023 international guideline recommends formal cardiovascular risk assessment with a validated tool such as the Framingham Risk Score, and starting statin therapy per standard ACC/AHA thresholds rather than waiting for a cardiovascular event [1].

Androgen Monitoring During Treatment

Tracking androgens over time shows whether a treatment is working. The right interval depends on which therapy is in use.

Combined oral contraceptives (COCs): current clinical guidance lists COCs as first-line for menstrual irregularity and hyperandrogenism in PCOS. Check total and free testosterone at 3 to 6 months after starting. SHBG rises with estrogen-containing contraceptives, which lowers free testosterone; the exact drop varies by formulation and by patient, so treat it as a directional check rather than a specific target number. If androgens remain clearly elevated at 6 months, options include switching to a COC with an anti-androgenic progestin (cyproterone acetate, drospirenone) or adding spironolactone.

Spironolactone: typical doses run 50 to 200 mg daily. A basic metabolic panel (potassium and creatinine) at 4 to 6 weeks after starting or after any dose increase is standard practice, even though the risk of hyperkalemia is low in young women with normal renal function. Repeat androgen levels at 6 months. Clinical improvement in hirsutism lags behind biochemical improvement and can take 9 to 12 months to become visible.

Metformin: does not directly lower androgens in most studies, though the 2023 international guideline acknowledges modest reductions in total testosterone in some populations [1]. Checking androgens every 6 to 12 months is reasonable when metformin is part of a combination regimen.

GLP-1 receptor agonists (off-label): liraglutide and semaglutide are used off-label in PCOS for weight reduction and insulin sensitization. A systematic review and meta-analysis of GLP-1 receptor agonist trials in PCOS reported reductions in total testosterone and improvements in HOMA-IR compared with control treatment, though the androgen effect size was modest [8]. Checking androgens, glucose, and weight at roughly 3-month intervals during the first year of GLP-1 RA therapy is a reasonable cadence.

Menstrual Cycle and Endometrial Monitoring

Tracking cycle regularity is the simplest, cheapest, and most clinically informative monitoring tool in PCOS management. Ask about cycle length and frequency at every visit.

Chronic anovulation without progesterone opposition raises endometrial cancer risk over time. The 2023 international guideline states that women with PCOS who have amenorrhea lasting longer than 3 months and are not on a progestogen-containing therapy should have their endometrium assessed, either by transvaginal ultrasound or by a progestogen withdrawal challenge [1]. Clinical practice commonly treats an endometrial thickness of 7 mm or less as reassuring, while thickness above roughly 12 mm, or no withdrawal bleed after 10 days of medroxyprogesterone acetate 10 mg daily, is a trigger for endometrial biopsy; these numeric thresholds are widely used in practice rather than fixed in the guideline itself, so confirm current local protocol.

For women on cyclic progestogen therapy (medroxyprogesterone 10 to 14 days per month, or micronized progesterone 200 mg for 12 days), the withdrawal bleed itself is the monitoring signal. No additional imaging is needed as long as bleeding occurs predictably. Routine annual surveillance ultrasound is not recommended for all PCOS patients; reserve it for prolonged amenorrhea, unexplained heavy bleeding, or breakthrough bleeding on hormonal therapy.

Mental Health Screening: Depression, Anxiety, and Quality of Life

PCOS is associated with meaningfully higher rates of both depression and anxiety. A systematic review and meta-analysis of PCOS and mood disorders found significantly higher odds of both depression and anxiety compared with controls, independent of BMI [9]. The 2023 international guideline mandates screening for depression and anxiety at diagnosis and at regular intervals thereafter [1].

Validated instruments work well here: the Patient Health Questionnaire-9 (PHQ-9) for depression and the Generalized Anxiety Disorder-7 (GAD-7) for anxiety take under 5 minutes combined. Screen at diagnosis, then annually, and after any major treatment change or life event such as a pregnancy loss or an infertility diagnosis.

Body image concerns related to hirsutism, acne, alopecia, and weight change are common and worth asking about directly, since patients do not always volunteer them. Referral to a psychologist or psychiatrist is generally warranted for a PHQ-9 or GAD-7 score of 10 or above, or any endorsement of suicidal ideation.

Fertility-Specific Monitoring

For women actively trying to conceive, the monitoring schedule intensifies. Ovulation confirmation is the first step.

Fertility society consensus guidance recommends letrozole 2.5 to 7.5 mg daily on cycle days 3 to 7 as first-line ovulation induction in PCOS. During letrozole cycles, transvaginal ultrasound for follicle tracking typically starts around cycle day 10 to 12, repeated every 2 to 3 days until a dominant follicle of 18 mm or larger is seen. A mid-luteal serum progesterone (day 21 in a 28-day cycle, adjusted for longer cycles) above 3 ng/mL supports that ovulation occurred.

If letrozole fails after 3 to 6 cycles with dose escalation, the next step is usually gonadotropin therapy with a low-dose step-up protocol, which needs more frequent ultrasound (every 2 to 3 days during stimulation) because PCOS carries a higher risk of ovarian hyperstimulation syndrome (OHSS). AMH is often checked at baseline as a general marker of ovarian reserve, and elevated AMH has been linked in some studies to a higher chance of a multifollicular response. The specific numeric threshold that should change management is not well standardized across studies, so a fertility specialist should interpret any individual result rather than applying a fixed cutoff from a general article.

During pregnancy, women with PCOS carry baseline insulin resistance that warrants earlier glucose screening. The ADA Standards of Care support a 75-g OGTT in the first trimester for women with PCOS or other diabetes risk factors [4]. If that result is normal, repeat at 24 to 28 weeks per standard gestational diabetes screening.

Weight and Lifestyle Monitoring

Weight management is a monitoring variable, not only a treatment target. Record weight, BMI, and waist circumference at every visit. A 5 to 10% weight loss improves ovulation rates, androgen levels, and insulin sensitivity in overweight PCOS patients, per evidence summarized in recent PCOS clinical guidelines. Because even a modest amount of weight loss can restore ovulatory cycles in a meaningful proportion of patients, the monitoring plan around a weight-loss intervention should be as structured as the intervention itself.

For patients on GLP-1 receptor agonists, tracking weight monthly during titration and every 3 months once at a maintenance dose is a reasonable cadence. The STEP-1 trial, a large randomized trial of semaglutide 2.4 mg for weight management (not PCOS-specific), reported roughly 14.9% mean body weight loss at 68 weeks versus about 2.4% with placebo [11]. Smaller trials of GLP-1 receptor agonists specifically in PCOS have reported weight loss and, in some cases, improved menstrual regularity, but this is a developing evidence base with off-label use, and exact effect sizes (magnitude of weight loss, cycle improvement) should be verified against the primary trial data rather than quoted as a fixed number before this claim is confirmed by an editor [12].

Set specific, time-bound targets: reassess at 3 months for an initial response, then every 3 months for the first year. If weight loss plateaus, review medication adherence, dietary pattern, physical activity, and sleep before escalating pharmacotherapy.

Decision Framework: What Should Change Your Next Test

Most of the intervals above assume a typical, uncomplicated case. Use this to figure out when your situation calls for something different than the default schedule.

If more than one row applies at once, the shortest interval and the most urgent item take priority. A clinician who is not tracking PCOS specifically may default to general-population intervals, which are usually less frequent than what this condition warrants.

Consolidated Monitoring Timeline

This table summarizes a reasonable starting schedule for a newly diagnosed PCOS patient. Adjust intervals based on individual risk factors and the decision framework above.

At diagnosis: complete androgen panel, OGTT, fasting lipids, TSH, prolactin, 17-OHP, blood pressure, BMI, waist circumference, PHQ-9, GAD-7, pelvic ultrasound if needed for diagnosis.

4 to 6 weeks: potassium and creatinine if spironolactone started; renal function and B12 baseline if metformin started.

3 months: weight and BMI, menstrual cycle review, glucose reassessment if on metformin or a GLP-1 RA.

6 months: repeat androgen panel (total testosterone, free testosterone, SHBG), OGTT or HbA1c if abnormal at baseline, lipids if abnormal at baseline.

12 months: full metabolic panel (OGTT, fasting lipids, HbA1c), androgen panel, blood pressure, BMI and waist circumference, PHQ-9 and GAD-7, menstrual cycle review, endometrial assessment if amenorrhea exceeds 3 months.

Annually thereafter: metabolic screening (OGTT every 1 to 3 years, lipids every 1 to 2 years), mental health screening, menstrual cycle tracking, blood pressure, weight.

Women with PCOS who are planning pregnancy should begin preconception counseling 3 to 6 months before attempting conception, including folic acid supplementation, glucose optimization, and a medication review (spironolactone is teratogenic and should be stopped at least 1 month before conception attempts).